Hoffmann has been vice-chair of Roche since 2006 and a board director since 1996. Among many other roles, he is a trustee of ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

CNBC's Angelica Peebles talks to Roche Pharma CEO Teresa Graham discusses why we're still in the early stages of the obesity ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...

HK inno.N markets Roches Avastin for cancer treatment in South Korea HK inno.N and Roche forge collaboration to boost cancer ...